H.C. Wainwright Thinks Femasys’ Stock is Going to Recover

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Femasys (FEMYResearch Report), with a price target of $8.00. The company’s shares closed last Thursday at $2.14, close to its 52-week low of $1.26.

According to TipRanks.com, Bodnar is a 1-star analyst with an average return of -2.9% and a 40.0% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as TransCode Therapeutics, Olema Pharmaceuticals, and Context Therapeutics.

Currently, the analyst consensus on Femasys is a Strong Buy with an average price target of $9.33.

See the top stocks recommended by analysts >>

Femasys’ market cap is currently $25.28M and has a P/E ratio of -2.94.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Femasys Inc is a biomedical company focused on transforming women’s healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. Its mission is to provide women with minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.

Read More on FEMY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More